NCT06837961View on ClinicalTrials.gov

LC-Plasma on Immune Response and Reducing Symptoms of Upper Respiratory Infectious Diseases

PHASE3RecruitingINTERVENTIONAL
Enrollment

220

Participants

Timeline

Start Date

April 29, 2025

Primary Completion Date

September 30, 2025

Study Completion Date

October 31, 2025

Conditions
Healthy VolunteerImmune Response
Interventions
DIETARY_SUPPLEMENT

LC-Plasma

1 tablet containing 50mg LC-Plasma is taken daily for 4 weeks

OTHER

Placebo

1 tablet containing 50mg MCC is taken daily for 4 weeks

Trial Locations (1)

4215

RECRUITING

Griffith University, Southport

All Listed Sponsors
collaborator

Kirin Holdings Company, Limited

INDUSTRY

lead

RDC Clinical Pty Ltd

INDUSTRY